On August 25, 2017, Press Conference (hereinafter referred to as “Press Conference”) of the “2017 China BioMed Innovation and Investment Conference” (hereinafter referred to as “2017 CBIIC”) was held in Beijing. Related leaders including Song Ruilin, Director of executive committee of organizing committee of CBIIC and Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Xu Shan, Secretary General of China Association for Medical Devices Industry (CAMDI) and senior official from Suzhou Industrial Park, and representatives of some supporters and international organizations including Australia Embassy, China, Canadian Business Commissioner Service (TCS), Government of British Columbia, Canada and National Foundation for Cancer Research (NFCR) attended the press conference. The Press Conference announced that 2017 CBIIC would be held in Suzhou Industrial Park from October 29-31 this year; the registration system both in Chinese and English and promotional website would be online on the same day of the Press Conference.

Executive President Song introduced the preparation of the conference briefly. He pointed out that the China’s policy macro environment of pharmaceutical innovation improved unceasingly, new policies on national drug regulatory reform launched continuously and CFDA’s formal entry into ICH all symbolized that China’s drug review and approval system and whole chain supervision and management reform were internationalized at a faster pace and its pharmaceutical industrial level was enhanced and internationalized at a full speed. The Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance (2017version) that was adjusted and issued in this February not only paid importance to and included some innovative drugs put on market in nearly 10 years, but also included supporting products of national major drug innovation and major scientific and technological special projects in the medical insurance catalogue, e.g. Apatinib and Chidamide. All these fully showed that China’s medical insurance payment system had supported medical innovative drugs substantially.

He pointed out particularly that international practice had proved that innovative development was closely linked to capital investment and innovative ability had a positive correlation with capital investment in that innovation gave capital opportunities and capital supported the development of innovation. On the National Conference on Financial Work held in July, President Xi Jinping especially emphasized that direct financing channels should be opened to better solve financing demands of market subjects like innovative enterprises; he also said that finance should serve the real economy. In order to fulfill the important spirit, this conference made powerful trials in the fields of building a bridge of cooperation between innovation and capital, opening financing channels of innovative enterprises and promoting capital to serve the real economy.

With its principles of “innovation, industrialization and internationalization”, PhIRDA has been working to promote pharmaceutical innovation and development in China and held a series of important meetings and exchanging activities domestically in recent years. In 2016, PhIRDA joined the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) formally and became the only member representing Chinese local pharmaceutical industry. In May 2017, PhIRDA, one of the most active social organizations in Chinese pharmaceutical industry, exhibited innovative achievements and situations of Chinese medicine to the world by publishing an article in Nature, which has won highly praise from the State Council

Established on August 28, 1991, Securities Association of China (SAC) has been rated as National Advanced Social Organization by Ministry of Civil Affairs consecutively with its three functions of “self-discipline, service and transmission”; by the end of 2016, the association had had 1,123 members, of which 129 were legal members, 845 ordinary members and 149 special members; it has been an industrial organization with great influence and authority in China’s security investment field.

CAMDI, which was established in 1991, is a national non-profit social organization built based on the principle of voluntariness of units or individuals in medical device related industries like medical device development, production, management, investment, product testing, certification consultation and education training. With State-Owned Assets Supervision and Administration Commission of the State Council as its professional authority, CAMDI with nearly 4,000 members is under the professional guidance of China Food and Drug Administration and is the most representative industrial organization in China’s medical device field.

In 2016, PhIRDA cooperated with SAC to hold the 2016 China BioMed Innovation and Investment Conference that provided a zero-distance communication and exchange platform for innovative enterprises and investors and won wide acclaim. The first conference included 8 important global clinical-trial data release and over 70 roadshows of innovative pharmaceutical projects, attracting over 1,500 participants from 220 investment institutions and more than 300 innovative pharmaceutical enterprises. These data illustrated not only the gradually enriched China’s pharmaceutical innovation results, but the fact that more and more international organizations and investment institutions have been focusing on China’s pharmaceutical innovation field due to its innovation development as well.

PhIRDA, SAC and CAMDI have decided to hold the 2017 CBIIC by giving play to their respective resource advantages this year. Under the theme of “Promote the Linkage between Social Capital and Pharmaceutical Innovation, Improve Innovation Capability of Pharmaceutical Industry”, 2017 CBIIC will focus on and discuss the policy trend of China’s pharmaceutical industry, trend of new medicine R&D as well as investment in international pharmaceutical area, and opening ceremony, clinical-trial data release, roadshow sessions and forums will be included. The highlights of this event are as follows:

1. Overall Designed and co-hosted by the Pharmaceutical Innovation Industry and Investment Community

2017 China BioMed Innovation and Investment Conference is co-hosted by Security Association of China (SAC), China Pharmaceutical Innovation and Research Development Association (PhIRDA) and China Association for Medical Devices Industry (CAMDI). Fully relying on the strength of members in the fields of pharmaceutical research and development and investment, SAC, PhIRDA and CAMDI bring together the leading experts of the advanced pharmaceutical research institutions, innovative companies and investment institutions as the organizing committee, and make preparation to secure the orderly promotion of the conference.

2. Strong attention from industry and support from international famous investment bank, publication, related institutions domestic and abroad and media.

Till now, supporters of 2017 CBIIC include Chinese Academy of Medical Sciences, China Academy of Chinese Medical Sciences, world famous international J.P. Chase & Co. (J.P. Morgan), Canadian Business Commissioner Service (TCS), Government of British Columbia, Canada and National Foundation for Cancer Research (NFCR), Japan Pharmaceutical Manufacturers Association(JPMA), Institute for Biotechnology and Medicine Industry (IBMI). Top scientific journal Nature will cover this event as the first professional media. Moreover, international financial media, pharmaceutical and investment professional media in China will be invited to cover 2017 CBIIC as well during the whole process.

3. Dialogue between leaders from related government authorities, scholars and experts domestic and abroad

The opening ceremony is on the morning of October 29, leaders from China Food and Drug Administration (CFDA) and National Health and Family Planning Committee (NHFPC) will give keynote speeches. Director-General Thomas Cueni from International Federation of pharmaceutical Manufacturers and Associations (IFPMA), two global heads from J.P. Morgan, entrepreneurs from top leading pharmaceutical companies and academicians in pharmaceutical industry will be invited to participate in the open ceremony as well.

4. Worldwide Participation

2017 China BioMed Innovation and Investment Conference will gather more than 400 pharmaceutical companies, medical device companies and R & D institutions, more than 300 investment institutions. Moreover, embassies in China from different countries and international industry organizations will send representative to participate in this event as well. The total number of participants is expected to exceed 2000. Negotiation areas will be provided to the attendees for further discussion on collaboration.

5. Held Clinical-Trial Data Release of Innovative Drugs

The conference will specifically arrange the Clinical-Trial Data Release of Innovative Drugs after the opening ceremony. Top leading pharmaceutical innovative projects will be released in this session, which is helpful for the investment community to rapidly and accurately know the latest developments of the research and development of innovative drugs in pharmaceutical industry, so as to grasp the best investment opportunity. It will also promote the social capital to be invested in pharmaceutical innovation in an early stage.

6. Medical devices roadshow session and investors’ exchanges sharing forum are included in this event

2017 CBIIC will not only set non-listed and listed pharmaceutical companies roadshow sessions, and medical devices roadshow session and investors’ exchanges sharing forum are included as well. So that all the related fields are included, which will facilitate the development of pharmaceutical industry in China; investors’ exchanges sharing forum will provide a platform for the exchanges between pharmaceutical industry and investment. 

7. The first international innovative project roadshow that further internationalized the exchange between innovation and investment

The conference will organize international roadshows for National Foundation for Cancer Research, Australia and Canada; institutions and organizations like J.P. Morgan, the famous international investment bank, JPMA, Embassy of Israel, IBMI will also organize innovative projects in the roadshows. The international innovative project roadshows will make the conference a significant platform for exchanges and cooperation between international medical innovation and investment.

The 2017 CBIIC, which constitutes a more authoritative, open and internationalized annual gala of brands, will attract not only drugs, medical device innovative products and capitals, but also many scholars and elites form medical industry and investment field. It will absorb social capitals that are further involved in the medical innovative industry so as to precipitate effective transformation of medical innovation achievements in China, constructing a medical innovative ecosystem that is of sustainable development, meeting the demands of clinical medication in China’s economic social development and contributing to a healthy China.